-
Product Insights
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) - Drugs In Development, 2024
Empower your strategies with our Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/Urogenital Atrophy) – Drugs In Development, 2024 report and make more profitable business decisions. Vaginal atrophy is the thinning, drying, and inflammation of the vaginal walls due to the body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning and urgency with urination, urinary tract infections, and urinary incontinence. Risk factors include smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning...
-
Product Insights
Dysmenorrhea - Drugs In Development, 2024
Empower your strategies with our Dysmenorrhea – Drugs In Development, 2024 report and make more profitable business decisions. Dysmenorrhea is the medical term for painful menstrual periods. It happens when uterus contracts to shed its lining. The pain typically begins just before your period and subsides after a few days. Primary dysmenorrhea refers to recurrent pain with no identifiable cause. Secondary dysmenorrhea results from conditions like endometriosis The Dysmenorrhea drugs in development market research report provide comprehensive information on the therapeutics...
-
Sector Analysis
Polycystic Ovarian Syndrome (PCOS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Polycystic Ovarian Syndrome (PCOS) Marketed and Pipeline Drugs Report Overview Polycystic Ovarian Syndrome (PCOS) is a complex condition characterized by elevated androgen levels, menstrual irregularities, and/or small cysts on one or both ovaries. It stands as the most prevalent hormonal disorder affecting females of reproductive age. Genetic and environmental factors are responsible for the etiology of this condition. Unhealthy lifestyle choices, dietary habits, or exposure to infectious agents tend to increase the risk of developing PCOS. Key Mechanisms of Action...
-
Sector Analysis
Female Sexual Dysfunction (FSD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Female Sexual Dysfunction (FSD) Marketed and Pipeline Drugs Report Overview Female sexual dysfunction (FSD) is an umbrella term that encompasses disorders of sexual desire, orgasm, arousal, and sexual pain that result in significant personal distress. FSD is a multifactorial, progressive problem that can occur at any stage of life. It is a complex neurovascular phenomenon that is under the control of psychological, neurovascular, and hormonal factors. Key Mechanisms of Action (Marketed) · Receptor Agonist · Enzyme Inhibitor · Receptor Antagonist...
-
Sector Analysis
Premature Labor (PL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Premature Labor (PL) Marketed and Pipeline Drugs Report Overview Premature/preterm labor (PL) is labor occurring after 20 and before 37 weeks gestation. Premature deliveries cause more than half of long-term morbidity and 75% of perinatal mortality. Premature labor is diagnosed primarily by history and symptoms. Symptoms of preterm labor include regular contractions before term gestational age associated with cervical change, pelvic pressure, menstrual-like cramps, watery vaginal discharge, and lower back pain. Although lower back pain is present in normal pregnancy as well,...
-
Sector Analysis
Female Contraceptives in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Female Contraceptives Market Report Overview The female contraceptives market sales across the 7MM was $7.8 billion in 2022. The market is expected to achieve a CAGR of less than 1% during 2022-2032. During the forecast period, sales of female contraceptives will increase in the UK due to the rising female population. Conversely, sales in France, Germany, Italy, and Spain markets will decrease owing to the declining female population. Female Contraceptives Market Outlook, 2022-2032 ($ Billion) Buy the Full Report to...
-
Sector Analysis
Menopausal Disorders (MD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Menopausal Disorders (MD) Marketed and Pipeline Drugs Report Overview Menopausal disorders are a permanent cessation of menstruation resulting in the loss of ovarian follicle development. In 2023, the highest number of prevalent cases of menopausal disorders were registered in India and China. Treatment guidelines for MD are well-established globally and at the country level and are updated periodically. For instance, in 2023, the US and China updated guidelines. In the US, guidelines were provided by the North American Menopause Society...
-
Product Insights
Polycystic Ovarian Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Polycystic Ovarian Syndrome Clinical Trials Market Report Overview The Polycystic Ovarian Syndrome clinical trial market research report provides an overview of the Polycystic Ovarian Syndrome clinical trials scenario. This report provides top-line data relating to the clinical trials on Polycystic Ovarian Syndrome and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Sector Analysis
EpiCast Report: Endometriosis – Epidemiology Forecast to 2025
Endometriosis is an estrogen-dependent disorder characterized by growth and appearance of endometrial cells or tissues in locations outside the uterus, which results in a series of chronic inflammatory reactions leading to scarring of tissues and adhesions of fibrous tissues in the pelvic region. The condition is often associated with severe dysmenorrhea, chronic pelvic pain, chronic fatigue, deep dyspareunia, ovulation pain, abnormal bleeding, and infertility. Endometriosis has the potential to disrupt the quality of life of women, leading to emotional distress,...
-
Product Insights
Male Hypogonadism Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Male Hypogonadism Global Clinical Trials Review, H2, 2016" provides an overview of Male Hypogonadism clinical trials scenario. This report provides top line data relating to the clinical trials on Male Hypogonadism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.